I-Mab Stock Price, News & Analysis

I-Mab (NASDAQ: IMAB) announced a virtual investor webinar scheduled for July 8, 2025, at 2:00pm EDT to discuss new data for givastomig, their Claudin 18.2 x 4-1BB bispecific antibody. The webinar will feature Dr. Samuel J. Klempner from Massachusetts General Hospital reviewing Phase 1b combination dose escalation data presented at ESMO GI 2025. The study evaluates givastomig combined with nivolumab and chemotherapy in first-line treatment for Claudin 18.2-positive metastatic gastric cancers, with data from 17 patients. The original data presentation will occur at ESMO GI on July 2, 2025, at 16:50 CEST. The webinar will include a Q&A session, and a replay will be available on I-Mab's website for 90 days.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on June 11, 2025, confirming that its American Depositary Shares (ADSs) had maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days, meeting the requirement under Nasdaq Listing Rule 5550(a)(2). This compliance was achieved on June 10, 2025, and Nasdaq has confirmed that the matter is closed. I-Mab's ADSs will continue to be listed and traded on the Nasdaq stock exchange.

I-Mab (NASDAQ: IMAB), a U.S.-based biotech company specializing in immuno-oncology, has announced its participation in the H.C. Wainwright virtual "HCW@Home" Series on June 17, 2025. The company's management team will engage in a fireside chat focused on Claudin 18.2 as a therapeutic target for gastric cancers, with particular emphasis on their drug candidate givastomig, a Claudin 18.2 x 4-1BB bispecific antibody. The discussion will feature CEO Sean Fu and CMO Phillip Dennis, moderated by H.C. Wainwright Senior Analyst Andres Maldonado. Notably, givastomig's Phase 1 dose escalation study results in combination with immunochemotherapy have been selected for presentation at the upcoming ESMO GI Cancers Congress on July 2, 2025.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025. The company's management will engage in a fireside chat and one-on-one meetings on June 5 at 3:45 PM ET.

Additionally, I-Mab revealed that new data regarding their lead program, givastomig, has been accepted for a Mini Oral presentation at the ESMO GI Cancers Congress 2025, taking place on July 2, 2025, in Barcelona, Spain.

I-Mab (NASDAQ: IMAB) reported Q1 2025 financial results and business updates. The company's lead program givastomig is progressing well, with new combination data selected for presentation at ESMO GI in July 2025. Financial highlights include $168.6 million in cash and investments as of March 31, 2025, providing runway into 2027. Q1 2025 showed improved financials with net loss of $3.2 million ($0.02 per share), compared to $16.3 million in Q1 2024. R&D expenses decreased to $0.8 million from $6.1 million year-over-year. The company completed patient enrollment ahead of schedule in the first of two Phase 1b dose expansion cohorts for givastomig, with data expected in 1H 2026. I-Mab maintains a strong focus on developing precision immuno-oncology agents for cancer treatment, particularly targeting gastric cancers affecting over 250,000 people globally.

I-Mab, a U.S.-based global biotech company, announced that their givastomig combination study abstract has been selected for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025.

The study focuses on combining givastomig with nivolumab and chemotherapy for cancer treatment. The congress will take place from July 2-5 in Barcelona, Spain. Chief Medical Officer Dr. Phillip Dennis expressed enthusiasm about the acceptance of their clinical data for presentation.

The company, which specializes in developing precision immuno-oncology agents, will provide additional details about the presentation as more information becomes available from the conference.

I-Mab (NASDAQ: IMAB) reported its full year 2024 financial results, highlighting progress in its givastomig Phase 1b combination trial for first-line gastric cancer. The company completed enrollment ahead of schedule in the first expansion cohort, with topline dose escalation data expected in 2H 2025.

Financial highlights include a strong cash position of $173.4 million as of December 31, 2024, providing runway into 2027. The company reported a net loss of $22.2 million for 2024, compared to $207.7 million in 2023. R&D expenses were $21.8 million, while administrative expenses reached $29.7 million.

Key developments include the completion of Greater China assets divestiture and business operations restructuring. The company is focusing on advancing givastomig, a CLDN18.2 x 4-1BB bispecific antibody, with Phase 1b dose expansion study results expected in 1H 2026.

I-Mab (NASDAQ: IMAB), a US-based global biotech company specializing in precision immuno-oncology treatments for cancer, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled to take place from April 7-10, 2025.

The company's management team will be present at this virtual healthcare event, which serves as a significant platform for biotechnology companies to showcase their developments and connect with industry stakeholders.

I-Mab (NASDAQ: IMAB) has received a deficiency notice from Nasdaq on March 19, 2025, for failing to meet the minimum bid price requirement of $1.00. The notice comes after the company's stock traded below this threshold from February 3 to March 18, 2025.

The company has been granted a 180-day compliance period until September 15, 2025, during which it must achieve a closing bid price of at least $1.00 for ten consecutive business days to maintain its Nasdaq Global Market listing. If unsuccessful, I-Mab may be eligible for an additional 180-day extension or face potential delisting.

While the notice does not immediately affect I-Mab's listing status, business operations, or SEC reporting requirements, the company is evaluating options to regain compliance and has expressed its intention to resolve the deficiency within the given timeframe.